Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 November 2021

The Council of the University of the Free State (UFS) carefully considered and approved a vaccination policy for the institution during its meeting on 26 November 2021. 

The aim of the COVID-19 Regulations and Required Vaccination Policy is to regulate access of staff, ad hoc contract workers, and students to all the university’s premises. The policy will be implemented as from 14 February 2022.

“The policy implies that the university does not force anyone to be vaccinated, but the institution has the right to require vaccination if you want to access the institution’s premises in order to protect our staff and students,” said Prof Francis Petersen, UFS Rector and Vice-Chancellor.    

Fiduciary duty to ensure safe and caring environment

“The UFS is a residential university that requires face-to-face engagement by both staff and students, and operational requirements entail that our staff, ad hoc contract workers, and students are regularly exposed to large groups on the three campuses. We have a fiduciary duty to ensure a safe and caring environment and to meet the health and safety obligations on the campuses,” said Prof Petersen. 

Since March 2020 and within the national lockdown levels, the institution has followed a predominantly online emergency-remote learning-and-teaching programme with a minimalistic approach to the return of staff and students to campus. Where possible and within the national lockdown levels, staff members have been working from home, except essential service employees and academic staff that were required to support students studying on campus in carefully managed face-to-face classes/interactions.  

“The viability of consistent remote working and study conditions is not in line with the culture and strategy of the UFS. Although a blended learning approach is supported, sole online learning will be detrimental to the quality of our graduates and the experience that the institution should offer to its students as a residential university,” said Prof Petersen.

Encouraging university community to vaccinate

The institution is greatly concerned about the number of staff, students, and ad hoc contract workers who have tested positive for COVID-19 since the commencement of the national lockdown. The pandemic has resulted in numerous individuals being placed in quarantine, testing positive or being incapacitated due to COVID-19 complications and deaths. “We believe that the policy will be a contributing factor in encouraging the entire university community to make the responsible decision to vaccinate,” said Prof Petersen.

Although the policy does not force anyone to vaccinate, it is aimed at restricting campus access to vaccinated persons, while at the same time considering applications for exemption based on medical and religious grounds, natural immunity objections, other legally acceptable exemptions, or those participating in clinical trials approved by the South African Health Products Regulatory Authority (SAHPRA). Employee and Student Vaccination Exemption Committees will evaluate applications for exemption. These committees will operate independently, and will include medical, religious, legal and psychology experts.

Vaccinated persons will be required to upload their vaccination certificates on an electronic platform to obtain access to campus. Staff, ad hoc contract workers, and students who are not vaccinated, who do not have an approved exemption or deferral, and who do not have a SARS COVID-19 PCR negative result that is not older than a week, will not be allowed access to the campuses or facilities. Only vaccinated students will be allowed to access on-campus accommodation. 

Students who are not vaccinated by 14 February 2022, will not be prevented from registering for the academic year, but can only access the campus if vaccinated or granted an exemption. 

Consultation process and thorough risk assessment

“The development of the policy was consulted widely with relevant internal stakeholders, among others, the university’s Senate, supporting it with an overwhelming 84%. The university also followed due process by referring the proposed policy to all its governance structures for consultation – including obtaining opinions from reputable legal firms in the country,” said Prof Petersen. 

According to Prof Petersen, the UFS has conducted a thorough risk assessment of the implementation of the policy, and a contingency plan is in place that will be implemented in the absence of full implementation of the policy. “We will consider following a flexible approach if we initially find that the rate of vaccinations is low. We will work tirelessly with government to accelerate the rate of vaccinations with the ultimate goal to obtain a high enough level of vaccinations to limit the transmission of the COVID-19 virus and create a safe work and study environment for our staff and students,” he said. 

VIEW the Roads to Return to Campus 2022 Infographic here



Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept